ORIGIN

Hertzel Gerstein

Interim Executive Director; Senior Scientist

Hertzel Gerstein is PHRI’s Interim Executive Director and Senior Lead of the Diabetes Scientific Program. He is also a Professor of Medicine at McMaster University where he holds the Population Health Research Institute Chair in Diabetes; an Endocrinologist; Director of the Boris Clinic Diabetes Care and Research Program; Chair of Diabetes Clinical Trials Network Canada; and a Fellow of both the Canadian Academy of Health Sciences and the Royal Society of Canada.

Gerstein pioneered and firmly established international long-term diabetes-focused outcomes trials as the norm to support Evidence-Based Diabetes Care. Randomized trials that he designed and led have collectively included more than 90,000 people with either diabetes or prediabetes to date, and have studied and identified clinically important, life-saving diabetes therapies. These trials were supported by the US National Institute of Health, the Canadian Institutes of Health Research, other Canadian peer-review agencies, and by industry. Together, they have substantially expanded the evidence-base pertaining to the prevention, remission, and treatment of diabetes and its consequences, and some of their findings have provided the evidence base for international diabetes guidelines and novel drug indications that have improved the lives of people living with diabetes or prediabetes.

His research has been published in over 600 papers and his h index is 100. His work has been recognized by many awards, including the 2012 Canadian Diabetes Association’s Lifetime Achievement Award and the 2022 American Diabetes Association’s Outstanding Achievement in Clinical Diabetes Research Award.

Salim Yusuf

Founder and Emeritus Executive Director, Senior Scientist

Salim Yusuf is an internationally renowned cardiologist and epidemiologist, whose work over 40 years has substantially influenced prevention and treatment of cardiovascular disease. Medically qualified from St John’s Medical College in Bangalore in 1976, he received a Rhodes Scholar-ship and obtained a DPhil from Oxford, during which he (along with Richard Peto, Rory Collins and Peter Sleight) initiated the concepts of large, simple trials, and meta-analysis. He coordinated the first ISIS trial (which established the structure for future international collaborative work in cardiovascular and several other diseases) that demonstrated the value of beta-blockers in myo-cardial infarction, and was a member of steering committees for all subsequent ISIS trials.

In 1984, following clinical training in medicine and cardiology in the UK, he moved to the National Institutes of Health, Bethesda, USA, where he led the SOLVD trial (establishing the value of ACE-inhibitors on LV dysfunction) and DIG trial (clarifying the role of digitalis).

In 1992 he moved to McMaster University as head of cardiology, where he established an inter-national program of research in cardiovascular diseases and prevention, culminating in the creation of the Population Health Research Institute. His therapeutic trials have established the roles of ACE-inhibitors in CVD prevention, dual antiplatelet therapies in acute coronary syndromes, novel antithrombotic therapies, and most recently the value of the polypill in substantially pre-venting heart attacks and strokes globally, and at low cost. The Polypill was recently included by the WHO in its Essential Medicines List.

His epidemiologic work in over 80 countries involving all inhabited continents of the world shows the majority of risks of both heart attacks and strokes are attributable to a few risk factors. He currently leads the PURE study exploring the role of societal and environmental factors in CVD. This study (PURE) involves 200,000 people from over 800 communities in 27 high, middle and low-income countries.

He has built capacity for clinical and population research across Canada and the world by establishing research networks involving over 1500 sites in 102 countries. He has trained over 100 researchers, many of whom are now nationally or internationally renowned leaders in medical research. He has helped develop major research institutes or programs in Canada, India, Argentina, Brazil, S. Africa, Saudi Arabia, Malaysia, and China.

He holds a Heart and Stroke Foundation of Ontario Research Chair, was a Senior Scientist of the Canadian Institutes of Health Research (1999-2004), and has received (among over 100) the Lifetime Research Achievement award of the Canadian Cardiovascular Society and the World Heart Federation, the Paul Wood Silver Medal of the British Cardiac Society, the European So-ciety of Cardiology gold medal, the American Heart Association Clinical Research Award, the Killam Prize, and the Canada Gairdner Wightman Award in 2014. He has been inducted into the Royal Society of Canada, been appointed an Officer in the Order of Canada, and has been in-ducted into the Canadian Medical Hall of Fame in 2014. In 2023 he was elected as an Honorary Fellow of St. John’s College, Oxford. He has been conferred 4 honorary doctorates.

He has published over 1400 articles, and was the second most cited researcher in the world for 2011, and has been among the highest cited scientists in the world (his H index is currently 17th of all scientists in history) for over a decade. He is Past President of the World Heart Federation, where he initiated the Emerging Leaders program (now named after him) to build capacity for research in all continents of the world, with the aim of halving the CVD burden globally within a generation. This program has already trained over 250 individuals from 50 countries.

Jackie Bosch

Scientist

Jackie Bosch is the Assistant Dean of the McMaster Occupational Therapy Program and a PHRI Scientist. She has a Bachelor’s degree in Occupational Therapy, a Master’s degree in Clinical Epidemiology and Biostatistics, and a PhD in Rehabilitation Science. She also serves as a Professor in the School of Rehabilitation and has an Adjunct Appointment with the University of Galway College of Medicine, Nursing, and Health Sciences.

Her research focuses on improving functional outcomes in clinical trials, particularly for stroke survivors in low-resource settings, and enhancing clinical trial methods. Bosch has taken on leadership roles in large-scale trials such as HOPE, HOPE-TOO, HOPE-3 (NCT00468923), DREAM (NCT00095654), ORIGIN (NCT00069784), TIPS-3 (NCT01646437), and COMPASS (NCT01776424). She leads the Organized Stroke Care Across Income Levels (OSCAIL) group, which has conducted a proof-of-concept study implementing key aspects of stroke unit care in hospitals within low-resource settings. Currently, the OSCAIL group is working on a community-based study aimed at improving outcomes for stroke survivors in these challenging environments. Bosch is also interested in optimizing how clinical trials are conducted, especially by finding new ways to make the start-up and execution processes more efficient.

Jackie Bosch has published 184 articles and received several awards, including the Lorna Reimer Award for Leadership from the Canadian Occupational Therapy Foundation in 2019 and the Faculty of Health Sciences, McMaster University, Programs Award for Graduate Students in 2014.

Jessica Tyrwhitt

Program Manager

Jessica Tyrwhitt has more than 10 years’ experience in coordinating and managing large, international clinical trials. She oversees interventional trials, registries, and observational research studies looking at primary and secondary prevention of cardiovascular disease in a variety of therapeutic areas, including cardiology, thrombosis, nephrology, cardio-oncology and diabetes.

She holds an Honours Bachelor of Science Degree & Business from the University of Waterloo.